Latest News for: rna

Edit

Self‑replicating circular RNA persists in extreme environments: Insights from hot spring microbiomes

Phys Dot Org 22 Apr 2026
... which are infectious RNA molecules that are smaller and structurally simpler than RNA viruses.
Edit

NSW Opens RNA Manufacturing Hub for Vaccines and Cancer Therapies

The Epoch Times 22 Apr 2026
New South Wales (NSW) has opened a $96 million RNA ... The new hub will produce messenger RNA (mRNA), synthetic RNA, lipid nanoparticles, and plasmid DNA on a small scale.
Edit

New method reveals structures of RNA-protein… (Baylor College of Medicine)

Public Technologies 22 Apr 2026
... how RNA works ... "RNA molecules perform many functions inside cells ... In the future, the method also could be applied to develop and optimize RNA-targeting drugs and RNA vaccines," Mustoe said.
Edit

Historic catalyst for NSW healthcare as $96 million RNA Research and Manufacturing Facility opens to support new therapeutic innovations (NSW Department of Premier and Cabinet)

Public Technologies 21 Apr 2026
Construction of the RNA Facility has been completed on time marking a new era in the state's ability to translate, develop and manufacture life-saving RNA therapeutics ... Paul McDonald, CEO, RNA Australia said..
Edit

RNA therapies: Würzburg nanotransporters against heart attacks (Julius-Maximilians-Universität Würzburg)

Public Technologies 21 Apr 2026
) RNA therapies ... The University of Würzburg is therefore researching customised therapies based on RNA ... are investigating how the transport capsules they have designed transport RNA within cells.
Edit

Historic catalyst for NSW healthcare as $96 million RNA Research and Manufacturing Facility opens to support new therapeutic innovations (State Government of New South Wales)

Public Technologies 21 Apr 2026
Construction of the RNA Facility has been completed on time marking a new era in the state's ability to translate, develop and manufacture life-saving RNA therapeutics ... Paul McDonald, CEO, RNA Australia said..
Edit

GROQ-seq Datasets Across Transcription Factors (LacI, RamR, VanR), T7 RNA Polymerase and TEV Protease (NIST - National Institute of Standards and Technology)

Public Technologies 20 Apr 2026
) Published. April 19, 2026. Author(s) ... Abstract ... Citation. BioRxiv ... (2026), GROQ-seq Datasets Across Transcription Factors (LacI, RamR, VanR), T7 RNA Polymerase and TEV Protease, BioRxiv, [online], https.//www.biorxiv.org/ (Accessed April 20, 2026).
Edit

Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development

PR Newswire 20 Apr 2026
Eclipsebio's eCOMPASS™ platform integrates AI-optimized RNA design (eNAVIGATE™), in-house prototyping at R&D scale, and deep sequencing-based characterization (eMERGE™) into a single iterative workflow.
Edit

CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform ...

The Indiana Times 18 Apr 2026
Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral componentsDemonstrating CREATE's leadership in in vivo immune cell engineering across T cells, NK cells, and myeloid cells ... .
Edit

Cells have a secret 'courier system' that could open hard-to-reach targets for RNA and gene therapies

Phys Dot Org 16 Apr 2026
A dense, stable droplet, this coating is made from the cell's own proteins and RNA, the molecules that control how cells operate and regulate themselves ... This allows the carried proteins and RNA to ...
Edit

New deep learning system helps scientists edit RNA - Children's National (Children's National Medical Center Inc)

Public Technologies 16 Apr 2026
The Children's National team built DeepCas13 on a newer and less studied CRISPR platform, called CRISPR-Cas13d, which instead focuses on RNA ... It is open source and available for free to researchers looking for targets to treat RNA-related diseases.
Edit

CEPI awards seed funding to Analysis Zero to advance real-time RNA vaccine quality testing using NMR technology (Recipharm AB)

Public Technologies 16 Apr 2026
CEPI funds Analysis Zero, a Recipharm company, to explore real-time RNA vaccine testing using NMR Aims to replace multi-day testing with real-time CQA monitoring Potential to speed batch release, cut costs and improve global access.
×